Acute esophageal variceal hemorrhage — resuscitation, vasoactive therapy, and endoscopic band ligation in the cirrhotic patient
Variceal hemorrhage is a medical emergency in patients with cirrhosis and portal hypertension. Hematemesis (bright red or coffee-ground) and melena in a patient with known or suspected cirrhosis should be assumed variceal until proven otherwise. Six-week mortality after a variceal bleed remains 15-20% even with modern therapy, so the first hour of resuscitation is as important as the endoscopic procedure itself.
Initial management mirrors any upper GI bleed but with cirrhosis-specific caveats:
• Access: two large-bore (16-18 gauge) peripheral IVs placed immediately; central access only if peripheral access fails • Airway protection: patients with active hematemesis, encephalopathy, or altered mental status warrant a low threshold for endotracheal intubation before endoscopy to prevent aspiration • Volume: judicious crystalloid resuscitation to restore perfusion, but avoid over-resuscitation — expanding plasma volume raises portal pressure and can dislodge a forming platelet-fibrin plug, worsening hemorrhage • Transfusion trigger: the landmark Villanueva et al. (NEJM 2013) trial randomized cirrhotic UGI bleed patients to restrictive (transfuse at Hgb <7 g/dL, target 7-9) versus liberal (transfuse at Hgb <9, target 9-11) strategy. Restrictive transfusion reduced further bleeding (10% vs 16%) and improved 45-day survival (95% vs 91%) • Mechanism: over-transfusion raises portal pressure (splanchnic blood volume expansion) and impairs the coagulation cascade's ability to form a stable clot at the bleeding varix — "more blood in, more blood out" • Exceptions to restrictive strategy: active massive hemorrhage with hemodynamic instability, coronary artery disease, or Hgb <7 regardless of symptoms • Correct coagulopathy cautiously: fresh frozen plasma and platelets are not given empirically/prophylactically — evidence in cirrhosis is weak and volume expansion itself raises portal pressure. Consider platelets if count <50,000/µL and active bleeding • Lactulose is often started early to prevent hepatic encephalopathy precipitated by the nitrogen load of digested blood in the gut
The single biggest resuscitation error is over-transfusion. Raising the hemoglobin above 9 g/dL in a bleeding cirrhotic increases portal pressure enough to provoke further variceal bleeding — treat the patient's hemodynamics, not a number on the chart.
Vasoactive drugs should be initiated as soon as variceal bleeding is suspected, ideally in the emergency department, well before the patient reaches the endoscopy suite — this is one of the few interventions proven to reduce both bleeding and mortality when started early.
Octreotide (somatostatin analog): • Mechanism: inhibits release of glucagon and other splanchnic vasodilator hormones, producing selective splanchnic vasoconstriction and reducing portal inflow/pressure • Dosing: 50 mcg IV bolus, followed by 50 mcg/hr continuous infusion, typically continued 2-5 days • Widely used in the US because of short half-life and favorable safety profile; less potent than terlipressin but has fewer systemic vascular complications
Terlipressin (synthetic vasopressin analog): • Mechanism: selective V1 receptor agonist on splanchnic vascular smooth muscle → potent splanchnic vasoconstriction, reduces portal pressure more than octreotide in some trials • Dosing: 2 mg IV every 4 hours until bleeding controlled (24h), then 1 mg every 4 hours; total duration up to 5 days • FDA-approved for hepatorenal syndrome in the US (2022); used for variceal bleeding worldwide, though availability varies by country • Watch for: cardiac ischemia, peripheral/mesenteric ischemia, hyponatremia — contraindicated in significant coronary or peripheral vascular disease
Somatostatin: an alternative to octreotide with similar mechanism, more commonly used in Europe; continuous infusion after bolus.
All vasoactive agents are continued for up to 5 days after index bleeding, spanning the highest-risk window for early rebleeding, and are used as an adjunct alongside — never a substitute for — endoscopic therapy.
Bacterial infection is present in 20% of cirrhotic patients at admission for GI bleeding and develops in another 50% during hospitalization — bacterial translocation across a congested, hyperpermeable gut wall is common during active hemorrhage and instrumentation.
• Regimen: ceftriaxone 1 g IV daily is the preferred agent, particularly in patients with advanced cirrhosis (Child-Pugh B/C), prior fluoroquinolone exposure, or in hospitals with high fluoroquinolone resistance • Alternative: oral norfloxacin 400 mg twice daily in patients with preserved renal function and lower-risk cirrhosis, though ceftriaxone has largely supplanted it • Duration: up to 7 days, or shorter if the patient is discharged sooner • Evidence: meta-analyses (Cochrane) show prophylactic antibiotics reduce rebleeding, bacterial infections (including spontaneous bacterial peritonitis), and all-cause mortality in cirrhotic patients with GI hemorrhage — one of the few antibiotic prophylaxis strategies in medicine with a clear mortality benefit • Rationale: infection independently predicts treatment failure and early rebleeding — inflammatory mediators released during sepsis promote further splanchnic vasodilation and raise portal pressure, creating a vicious cycle • Applies to ALL cirrhotic patients presenting with any GI hemorrhage (variceal or non-variceal), not just confirmed variceal bleeders, given the high pretest probability and steep downside of missing early sepsis
Once airway, breathing, and circulation have been addressed and vasoactive drugs and antibiotics started, esophagogastroduodenoscopy (EGD) is performed to confirm the diagnosis, identify the bleeding point, and deliver endoscopic hemostatic therapy in the same procedure. Timing and stigmata assessment directly guide urgency and technique.
Baveno VII consensus and the AASLD practice guidance both recommend upper endoscopy within 12 hours of presentation once the patient has been hemodynamically resuscitated — earlier does not consistently improve outcomes and may be dangerous in an unstable patient, while delaying beyond 12-15 hours is associated with higher mortality.
• Sequence matters: resuscitate first (IV access, fluids/blood as needed per restrictive strategy, vasoactive drug, antibiotic), then scope — endoscopy in a hypotensive, poorly oxygenated patient is itself a major risk • Airway protection: patients with ongoing hematemesis, depressed mental status (hepatic encephalopathy grade ≥2), or inability to protect their airway should be intubated before the procedure • Prokinetic pre-treatment: IV erythromycin (250 mg, 30-120 min before EGD) or metoclopramide can be given to empty gastric blood/clot and improve visualization, shown to reduce need for repeat endoscopy • Personnel: procedure should be performed or supervised by an endoscopist experienced in variceal hemostasis, with anesthesia support and the ligation device immediately available — "scope-and-treat" in one session
Precise description of the varix and any stigmata guides both the diagnosis of variceal bleeding as the cause and the technical approach:
Stigmata of recent hemorrhage (in decreasing order of bleeding risk): • Active spurting: pulsatile jet of blood — unequivocal culprit lesion • Active oozing: slow ongoing bleeding without pulsatile jet • Nipple sign (also called "platelet plug" or "white nipple sign"): a protruding white/red plug of platelet-fibrin aggregate marking a recently sealed rupture point — the single most specific sign of the culprit varix even without active bleeding • Red wale marks: longitudinal, whip-like red streaks on the variceal surface, representing dilated intraepithelial venules — predict a high risk of bleeding within the next weeks • Adherent clot: dark red/black clot stuck to a varix, often overlying a nipple sign
Variceal size grading (endoscopic, most widely used simplified scheme): • Small varices: minimally elevated veins above the esophageal mucosa • Large varices: occupy significant lumen and may nearly touch each other
Alternative French/Japanese "F" grading (used interchangeably in many reports): • F1: small, straight varices that flatten with air insufflation • F2: moderately enlarged, tortuous varices occupying less than a third of the lumen • F3: large, tortuous, coil-shaped varices occupying more than a third of the esophageal lumen — highest bleeding risk
Combining size/grade with red signs (red wale marks, cherry-red spots, hematocystic spots) forms the North Italian Endoscopic Club (NIEC) index used to predict first bleeding risk in unruptured varices.
Not every cirrhotic upper GI bleed is from an esophageal varix, and the endoscopist must survey the entire upper tract:
• Gastric varices: classified as gastroesophageal varices (GOV1 extending along the lesser curve, GOV2 extending into the fundus) or isolated gastric varices (IGV1 in the fundus, IGV2 ectopic) — fundal varices bleed less often but more massively, and typically require cyanoacrylate glue injection rather than banding • Portal hypertensive gastropathy: a diffuse "snakeskin" mosaic mucosal pattern causing chronic oozing rather than the massive hemorrhage typical of a ruptured varix — managed with nonselective beta-blockers, not endoscopic therapy • Peptic ulcer disease and Mallory-Weiss tears: cirrhotic patients are not immune to ordinary causes of UGI bleeding and these must be excluded or concurrently treated • Portal hypertensive duodenopathy and ectopic varices (duodenal, rectal, stomal): rarer sources that require a high index of suspicion when esophagogastric sources are absent
Endoscopic variceal ligation (EVL) is the first-line endoscopic hemostatic technique for esophageal varices, having replaced sclerotherapy in most centers because it achieves comparable or superior hemostasis with substantially fewer complications. A multi-band ligating device mounted on the endoscope tip mechanically strangulates each varix at its base with an elastic O-ring.
Modern variceal ligation uses a pre-loaded multi-band ligating device that mounts onto the endoscope tip, eliminating the need to withdraw and reload the scope after every single band (as required with older single-fire devices):
• Device: a clear plastic cylinder ("cap") loaded with 6-10 elastic O-rings, each connected to a trip-wire that runs through the endoscope's working (or an accessory) channel to a handle at the proximal end • Approach: the endoscope with mounted cap is advanced to just above the target varix, usually beginning near the gastroesophageal junction (highest-pressure, highest-risk zone) and working proximally • Suction: the target varix is drawn up into the cap by continuous endoscopic suction until the endoscopic view "whites out" — indicating the varix has filled the cap and formed a bulging pseudopolyp of mucosa and submucosal vessel • Firing: the trip-wire is pulled, releasing the pre-loaded elastic band, which snaps around the neck of the suctioned tissue, cinching it off from the circulation before the scope is withdrawn from suction • Repeat: the cap rotates to the next pre-loaded band and the process is repeated on the next varix column without removing the endoscope
The therapeutic effect of banding unfolds over days to weeks through a predictable sequence of tissue injury and healing:
1. Mechanical occlusion: the elastic band immediately occludes blood flow into the captured varix and overlying mucosa, achieving instantaneous hemostasis if active bleeding was present 2. Ischemic necrosis: the strangulated pseudopolyp becomes ischemic within hours; the mucosa and superficial submucosal vessel undergo coagulative necrosis 3. Thrombosis: stagnant blood within the banded varix segment thromboses, obliterating that segment of the vessel 4. Sloughing: the necrotic pseudopolyp, band, and thrombosed vessel remnant slough off the esophageal wall over roughly 2-7 days, leaving a shallow, discrete mucosal ulcer at the ligation site 5. Fibrosis: as the post-band ulcer heals over the following 1-3 weeks, submucosal fibrosis develops at the ligation site, permanently obliterating that varix segment and reducing the likelihood of recurrence at that specific column
Because each band only treats a focal segment of a single varix column, and varices are continuous vessels running the length of the distal esophagus, sequential banding of the entire visible variceal length — and repeat sessions over subsequent weeks — is required to achieve durable eradication.
Endoscopic sclerotherapy (injection of a sclerosant such as ethanolamine oleate or sodium tetradecyl sulfate directly into or beside the varix) was the original endoscopic technique but is now reserved for varices too small to band or as a rescue technique, because head-to-head trials and meta-analyses consistently favor banding:
• Rebleeding: EVL is associated with lower rates of rebleeding than sclerotherapy • Local complications: sclerotherapy causes a deep chemical injury through the mucosa and submucosa, leading to esophageal ulceration, stricture formation (up to 15% of patients), perforation, and mediastinitis in severe cases; banding is a superficial mechanical injury confined to the mucosa, with strictures occurring in only 1-2% • Mortality: several trials and meta-analyses show a modest mortality advantage with EVL • Sessions to eradication: banding typically requires fewer sessions to achieve total variceal obliteration than sclerotherapy
Sclerotherapy retains a niche role for varices too small to be safely suctioned into a band ligator cap, and it remains standard for treating actively bleeding gastric varices with cyanoacrylate glue injection (a related but distinct technique from esophageal sclerotherapy).
Endoscopic variceal ligation is now recommended by AASLD and Baveno VII as the first-line endoscopic modality for both active esophageal variceal hemorrhage and primary/secondary prophylaxis of varices, having demonstrated a superior safety profile to sclerotherapy without sacrificing efficacy.
A single band controls a single bleeding point, but esophageal varices exist as several continuous longitudinal columns. A therapeutic banding session systematically places multiple bands along each visible varix, and — combined with ongoing vasoactive drug and antibiotic therapy — this achieves hemostasis in the large majority of patients.
Within a single therapeutic session, the endoscopist aims to obliterate as much of the visible variceal column as safely possible, following a systematic pattern rather than banding haphazardly:
• Starting point: banding classically begins near the gastroesophageal junction, where wall pressure and rupture risk are highest, and proceeds proximally in a spiral pattern up each varix column — though many endoscopists begin more distally and work upward specifically to avoid obscuring the field with blood from a more proximal band before the distal (higher-risk) segment has been treated • Spacing: bands are placed 1-2 cm apart along and between columns, spiraling around the circumference of the esophagus rather than placing many bands in a single longitudinal line, to reduce the risk of a confluent circumferential injury that could narrow the lumen • Number: a typical session places 4-10 bands, limited by the number of pre-loaded rings on the device (commonly a 6- or 10-band cap), the number of visible varix columns (usually 3-5 in the distal esophagus), and the tolerance of the mucosa to further injury in one sitting • Avoiding contiguous circumferential banding: placing bands directly opposite each other at the same esophageal level in a single session, or banding an entire circumference, raises the risk of stricture and is generally avoided — de-tiered/spiral technique minimizes this risk
The evidence base strongly supports combining a vasoactive drug with endoscopic therapy rather than relying on either alone:
• Pharmacotherapy alone: variable control rates, often quoted around 65-75% • Endoscopic therapy alone: similarly incomplete without the splanchnic pressure reduction achieved pharmacologically • Combined vasoactive drug + EVL: control of bleeding in more than 90% of episodes — this is now the standard of care in essentially all published guidelines • Failure to control bleeding at 5 days (or bleeding recurring within that window) defines "treatment failure" and is the trigger for escalation to rescue therapy (covered in Stage 5) • Mechanism of synergy: the vasoactive drug reduces portal inflow and pressure across the entire portal venous system (including any varices not yet banded and areas of gastric or duodenal portal hypertensive mucosa), while banding provides immediate, definitive mechanical control at the identified bleeding point — together they address both the pressure driving rupture and the ruptured vessel itself
EVL is markedly safer than sclerotherapy but is not free of risk:
• Post-banding ulcer bleeding: the ligation site ulcer left after the band and necrotic tissue slough off (2-7 days post-procedure) can itself bleed in roughly 5% of patients, occasionally requiring repeat endoscopy — this is why proton pump inhibitor or sucralfate therapy is sometimes used to promote ulcer healing, and patients are counseled to report bleeding in the week following the procedure • Dysphagia and chest discomfort: transient, mild, related to esophageal edema/spasm at band sites, usually self-limited over 1-3 days • Esophageal stricture: rare (1-2%) compared to sclerotherapy, more likely with dense circumferential banding over multiple sessions • Bacteremia: transient bacteremia can occur with any endoscopic esophageal procedure, reinforcing the rationale for periprocedural antibiotic prophylaxis already given for the index bleed • Perforation: very rare with banding (far more of a concern with sclerotherapy or forceful cap suction of a friable, previously sclerosed esophagus) • Aspiration: a periprocedural risk in any actively bleeding, poorly protected airway, independent of the banding technique itself
A single banding session rarely eradicates all varices. Patients return for repeat sessions on a fixed interval until the varix columns are obliterated, all while carrying a meaningful risk of early rebleeding that is highest in the first days after the index bleed. When bleeding cannot be controlled or recurs early despite optimal therapy, rescue interventions — TIPS or balloon tamponade — are required.
Because a single session cannot safely obliterate every column without excessive circumferential injury, patients undergo staged, repeat EVL sessions:
• Interval: repeat sessions are scheduled every 2-4 weeks, allowing prior ligation ulcers to heal and fibrose before further instrumentation of the same field • Number of sessions: variceal eradication (defined as small or absent residual varices unable to be further banded) typically requires 2-4 sessions total, though this varies with the severity of underlying portal hypertension and the number of columns initially present • Endpoint: "eradication" does not mean the underlying portal hypertension has resolved — it means the visible esophageal varix columns have been obliterated to the point where further banding is not feasible; new varices can still form over time as portal pressure persists • Documentation: each session should record the number and location of varices banded and residual variceal grade to track progress toward eradication and to compare against future surveillance exams
Despite combined pharmacologic and endoscopic therapy, 10-20% of patients will have uncontrolled bleeding or early recurrent bleeding (within 5 days), termed treatment failure — this population requires urgent rescue therapy:
Transjugular intrahepatic portosystemic shunt (TIPS): • Mechanism: an interventional radiologist creates a low-resistance channel between the portal vein and hepatic vein through the liver parenchyma, directly decompressing the portal system regardless of the site of variceal bleeding • Rescue/salvage TIPS: performed emergently in patients with uncontrolled or recurrent bleeding despite banding and vasoactive drugs — controls bleeding in the large majority of these otherwise refractory cases • Early ("pre-emptive") TIPS: placed within 24-72 hours of admission in selected high-risk patients (Child-Pugh C 10-13 or Child-Pugh B with active bleeding at endoscopy) even before treatment failure occurs — shown in randomized trials (García-Pagán et al.) to reduce rebleeding and improve survival compared to a "rescue-only" approach • Complications: hepatic encephalopathy (a decompressive shunt bypasses hepatic clearance of gut-derived toxins), shunt stenosis/thrombosis over time
Balloon tamponade (Sengstaken-Blakemore or Minnesota tube): • Role: a temporizing bridge, not definitive therapy — mechanically compresses the bleeding varix via inflated gastric and/or esophageal balloons when bleeding is massive and uncontrolled • Duration: should not remain inflated more than 24 hours because of the risk of pressure necrosis, esophageal rupture, and aspiration; used only until definitive therapy (repeat endoscopy, TIPS) can be arranged • Requires airway protection (intubation) given high aspiration risk • Self-expanding covered esophageal metal stents are an alternative bridge to definitive therapy at some centers, allowing longer dwell time than balloon tamponade with a lower complication rate
After the acute bleeding episode is controlled, every patient requires secondary prophylaxis to prevent rebleeding — the risk of a further variceal hemorrhage without prophylaxis approaches 60% within 1-2 years.
• Nonselective beta-blockers (NSBB): propranolol or carvedilol reduce portal pressure through beta-1 blockade (decreased cardiac output/portal inflow) and unopposed alpha-mediated splanchnic vasoconstriction (beta-2 blockade). Carvedilol adds intrinsic alpha-1 blocking activity, producing a greater HVPG reduction than propranolol in many studies and is increasingly favored • Dosing: propranolol titrated to the maximum tolerated dose or a resting heart rate of 55-60 bpm; carvedilol typically started at 6.25 mg daily and titrated as tolerated • Combination therapy: current guidelines (Baveno VII, AASLD) recommend NSBB plus continued surveillance EVL together for secondary prophylaxis, as combined therapy reduces rebleeding more than either modality alone • Surveillance endoscopy: after eradication is achieved, repeat EGD is performed every 3-6 months initially (then may be spaced out) to detect variceal recurrence, since portal hypertension persists and new columns can form even after prior eradication • HVPG-guided therapy: where available, hepatic venous pressure gradient measurement can confirm an adequate hemodynamic response to beta-blockade (a drop in HVPG to <12 mmHg, or a reduction of ≥20% from baseline, is associated with a markedly lower rebleeding risk) — though this invasive measurement is not universally accessible and treatment is often guided clinically
Baveno VII endorses combining a nonselective beta-blocker with continued endoscopic band ligation for secondary prophylaxis rather than either alone — this combined strategy produces the lowest rebleeding rates of any regimen studied, reflecting the complementary mechanisms of systemic portal pressure reduction and focal mechanical obliteration of residual varices.